Loxo Oncology (NASDAQ:LOXO) Institutional Investor Positioning

April 22, 2018 - By Clifton Ray

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Sentiment for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) institutional sentiment decreased to 0.97 in 2017 Q4. Its down -0.76, from 1.73 in 2017Q3. The ratio turned negative, as 70 funds opened new and increased holdings, while 72 reduced and sold their positions in Loxo Oncology. The funds in our partner’s database now possess: 124.82 million shares, up from 29.06 million shares in 2017Q3. Also, the number of funds holding Loxo Oncology in their top 10 holdings decreased from 6 to 5 for a decrease of 1. Sold All: 29 Reduced: 43 Increased: 47 New Position: 23.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $4.00 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

The stock decreased 0.29% or $0.39 during the last trading session, reaching $133.06. About 173,193 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 146.80% since April 22, 2017 and is uptrending. It has outperformed by 135.25% the S&P500.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on May, 8. They expect $-0.60 EPS, up 37.50 % or $0.36 from last year’s $-0.96 per share. After $-0.69 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts -13.04 % EPS growth.

Aisling Capital Llc holds 57.19% of its portfolio in Loxo Oncology, Inc. for 3.44 million shares. Dafna Capital Management Llc owns 296,000 shares or 13.42% of their US portfolio. Moreover, Opaleye Management Inc. has 4.75% invested in the company for 176,300 shares. The Illinois-based Driehaus Capital Management Llc has invested 1.83% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 152,185 shares.

Since January 1, 0001, it had 0 insider buys, and 16 selling transactions for $70.72 million activity.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Ratings analysis reveals 100% of Loxo Oncology’s analysts are positive. Out of 8 Wall Street analysts rating Loxo Oncology, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $95.0 while the high is $151. The stock’s average target of $119.67 is -10.06% below today’s ($133.06) share price. LOXO was included in 12 notes of analysts from November 2, 2017. The stock has “Overweight” rating by Morgan Stanley on Monday, April 16. The rating was downgraded by Morgan Stanley on Wednesday, March 21 to “Equal-Weight”. The firm earned “Buy” rating on Monday, March 5 by Citigroup. The company was upgraded on Tuesday, November 14 by IFS Securities. JMP Securities upgraded the stock to “Buy” rating in Tuesday, November 14 report. The stock has “Buy” rating by BTIG Research on Wednesday, December 20. Stifel Nicolaus maintained it with “Buy” rating and $135.0 target in Thursday, March 1 report. The rating was maintained by Citigroup on Thursday, November 16 with “Buy”. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Buy” rating by Stifel Nicolaus on Thursday, November 2. As per Thursday, February 22, the company rating was initiated by Oppenheimer.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.